



12-27-99

2-81616 7B
JF 1/1/00

GEI-067

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
M. LANQUETIN et al
Serial No.: 284,147
Filed: April 7, 1999
For: HORMONAL...COMPOUND

: S. Qazi
:
: Group: 1616
:
:

600 Third Avenue
New York N.Y. 10016
December 23, 1999

RECEIVED

RE
JAN 03 2000

TECH CENTER 1600/2900
TECH CENTER 1600/2900

AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the office action of September 23, 1999, please
amend this application as follows:

IN THE SPECIFICATION:

Page 3, lines 19 and 22; page 4, lines 4 and 8; page 5, line
2; page 6, line 17, cancel "conjugated" and before "equine", insert
--conjugated--

Page 4, line 10, before "equine", insert --conjugated--
line 11, cancel "conjugated"

IN THE CLAIMS:

Cancel all pending claims and add the following claims:

--21. A method of treating estrogenic deficiencies or
osteoporosis and cardiovascular illness in post-menopausal women or
stopping ovulation in women during their period of ovarian activity
comprising simultaneously administering orally to said women, from
21 to 25 days per month, in combination an effective amount of

19 10/2/99
EL 323 901 235 US
DEC 23, 99
The fee of \$100.00 per paper or fee is
to be paid to the United States Postal
Service, Department of Commerce, Patent
and Trademark Office, P.O. Box 1000,
Washington, D.C. 20231, on or before
the date of mailing of this communication.
Addressed to the Commissioner of
Patents and Trademarks, P.O. Box 1000,
Washington, D.C. 20231.

Wane - Inure Ruler
12/23/99

B1